Eupolio (sabin inactivated poliovirus vaccine) / Intravacc, Sinovac - LARVOL DELTA

A multi-center, open-labelled, randomized controlled extended phase III non-inferiority clinical trial to evaluate the immunogenicity and tolerability of poliomyelitis vaccine (Vero cells), inactivated, Sabin strains administered with or without routine infant vaccines. (PubMed, Vaccine) - P3 | "Our results demonstrated favorable safety and immunogenicity of co-administration of sIPV with other routine infant vaccines according to a 3-dose primary immunization schedule."

Head-to-Head • Journal • P3 data • Infectious Disease

Safety of Sabin-Strain Inactivated Poliovirus Vaccine Administered Alone or Concomitantly with Other Vaccines: A Population-Based Post-Marketing Surveillance Study. (PubMed, Vaccines (Basel)) - " Sabin-strain inactivated poliovirus vaccine demonstrated a favorable safety profile when administered either alone or concomitantly with other vaccines. These findings support the continued use of flexible and synchronized vaccination strategies involving Sabin-strain inactivated poliovirus vaccine in routine immunization programs."

Journal • P4 data • Infectious Disease

Booster Dose of sIPV Co-administered With MMR and HepA-I. (clinicaltrials.gov) - P4 | N=889 | Completed | Sponsor: Sinovac Biotech Co., Ltd | Not yet recruiting ➔ Completed | Trial completion date: Mar 2025 ➔ Oct 2025 | Trial primary completion date: Feb 2025 ➔ Sep 2025

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease

A Multi-center, Open-labelled, Randomized, Controlled, Extended Phase Ⅲ Clinical Trial of sIPV Vaccine (clinicaltrials.gov) - P3 | N=1442 | Completed | Sponsor: Sinovac Biotech Co., Ltd | Recruiting ➔ Completed | Trial primary completion date: May 2024 ➔ Feb 2025

Trial completion • Trial primary completion date • Infectious Disease

Immunogenicity and Safety of Sabin Strain Inactivated Poliovirus Vaccine Booster Dose Administered Separately or Concomitantly with Inactivated Hepatitis A Vaccine or Measles-Mumps-Rubella Combined Attenuated Live Vaccine: An Open-Labelled, Randomized, Controlled, Phase 4 Clinical Trial. (PubMed, Vaccines (Basel)) - P4 | "Same-day sIPV co-administration with MMRV or HepA was non-inferior and well tolerated, supporting programmatic adoption."

Journal • P4 data • Infectious Disease • Inflammation • Measles • Mumps • Rubella

Teupolioside and Graminex (Xipag®) combined therapy induced anti-inflammatory effects and decreased dihydrotestosterone levels in the prostate tissue of patients with benign prostate hyperplasia: results of a pilot study. (PubMed, Minerva Urol Nephrol) - "The short period of Xipag® administration effectively reduced DHT and PSA levels in patients affected by BPH. Additionally, it decreased CD4+ T lymphocyte infiltration while promoting CD8+ T lymphocytes, leading to a normalization of the prostate tissue inflammatory infiltrate."

Journal • Benign Prostatic Hyperplasia • Inflammation • CD4 • CD8

Sexual safety and efficacy of a pollen extract and teupolioside-based supplement in men with benign prostatic hyperplasia: a prospective observational study. (PubMed, Arch Ital Urol Androl) - "The pollen extract and teupolioside supplementation was well tolerated and associated with improved QoL and urinary outcomes, without compromising sexual or ejaculatory function. These findings support its potential as a non-pharmacologic adjunct in the management of BPH, particularly in patients concerned about sexual side effects. Further randomized controlled studies are warranted to confirm these results."

Journal • Observational data • Benign Prostatic Hyperplasia • Sexual Disorders

Quantification of the Role of Teupol® 25P and Graminex® G96 Compared to Hexanic Extract of Serenoa repens in Patients Affected by Lower Urinary Tract Symptoms During Treatment with Silodosin. (PubMed, Medicina (Kaunas)) - "Xipag® is a novel formulation containing Graminex® G96 (pollen extract) and Teupol® 25P (teupolioside), offering anti-inflammatory and antiandrogenic effects. These findings support the use of multi-target nutraceuticals like Xipag® as a valuable adjunct in the management of LUTS/BPH. Larger randomized trials are warranted to confirm these results and explore underlying mechanisms."

Clinical • Journal • Observational data • Benign Prostatic Hyperplasia

Immunogenicity and safety of sequential Sabin strain inactivated poliovirus vaccine from different manufacturers in infants: Randomized, blinded, controlled trial. (PubMed, Vaccine) - "Sequential vaccination with sIPV from different manufacturers demonstrated superior immunogenicity compared to the initial vaccine, with no significant safety differences, indicating that using vaccines from different manufacturers for sequential dosing is a feasible and effective option."

Journal

Sustained Immune Persistence Five Years Post-Completion of Four-Dose sIPV Vaccination. (PubMed, Vaccines (Basel)) - "The sIPV maintains good immunological persistence five years after four doses of vaccination, with nAb GMT exceeding the seroprotecting threshold, suggesting that booster doses might be currently unwarranted."

Journal

Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule With Bivalent OPV in Infants (clinicaltrials.gov) - P3 | N=2001 | Completed | Sponsor: LG Chem | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease

Discovering a new nutraceutical based on pollen extract and teupolioside: a prospective monocentric study evaluating its role in alleviating lower urinary tract symptoms in benign prostatic hyperplasia patients. (PubMed, Arch Ital Urol Androl) - "The combination of pollen extract and teupolioside effectively alleviates LUTS in BPH patients with a favorable safety profile, particularly in avoiding sexual dysfunction."

Journal • Benign Prostatic Hyperplasia • Inflammation • Sexual Disorders

Sequential Vaccination of Poliomyelitis Vaccine (Vero Cells), Inactivated, Sabin Strains From Different Manufacturers (clinicaltrials.gov) - P4 | N=200 | Completed | Sponsor: Sinovac Biotech Co., Ltd | Not yet recruiting ➔ Completed

Trial completion • Infectious Disease

Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule with Bivalent OPV in Infants (clinicaltrials.gov) - P3 | N=2000 | Active, not recruiting | Sponsor: LG Chem | Recruiting ➔ Active, not recruiting | Phase classification: P3b ➔ P3

Enrollment closed • Phase classification • Infectious Disease

Safety and 6-month immune persistence of inactivated poliovirus vaccine (Sabin strains) simultaneously administrated with other vaccines for primary and booster immunization in Jiangxi Province, China. (PubMed, Vaccine) - "sIPV demonstrated good safety and immune persistence for primary and booster vaccinations, whether administered singly or simultaneously. Antibodies against hepatitis A, measles, mumps and rubella were not disrupted by the co-vaccination. However, the seropositivity rates and geometric mean concentrations (GMCs) of antibodies against pertussis indicate the necessity for a booster dose."

Journal • Hepatology • Infectious Disease • Inflammation • Measles • Mumps • Pertussis • Respiratory Diseases • Rubella

Booster Dose of sIPV Co-administered With MMR and HepA-I. (clinicaltrials.gov) - P4 | N=960 | Not yet recruiting | Sponsor: Sinovac Biotech Co., Ltd

New P4 trial • Infectious Disease

A Narrative Review of Herbal Remedies for Managing Hirsutism. (PubMed, Int J Prev Med) - "The results suggested that various herbs, including fennel, licorice, spearmint, saw palmetto, green tea, combination of Zingiber and neem, curcumin, and teupolioside have the potential as herbal remedies for hirsutism. However, further extensive well-designed studies involving a large sample size on the most promising herbs are necessary to determine their efficacy."

Journal • Review • Aesthetic Medicine • Cardiovascular • Hepatology • Myocardial Infarction • Osteoporosis • Pain • Rheumatology

Sequential Vaccination of Poliomyelitis Vaccine (Vero Cells), Inactivated, Sabin Strains From Different Manufacturers (clinicaltrials.gov) - P4 | N=200 | Not yet recruiting | Sponsor: Sinovac Biotech Co., Ltd

New P4 trial • Infectious Disease

Immune Persistence following Primary Immunization and the Immunogenicity and Safety of a Booster Dose of a Multidose Sabin Strain-Based Inactivated Polio Vaccine in Infants Aged 18 Months. (PubMed, Vaccines (Basel)) - "The 5-dose sIPV has shown promising immune persistence and robust immune response following a booster immunization, coupled with an acceptable safety profile."

Journal • Infectious Disease

Teucrium montanum L.-Unrecognized Source of Phenylethanoid Glycosides: Green Extraction Approach and Elucidation of Phenolic Compounds via NMR and UHPLC-HR MS/MS. (PubMed, Antioxidants (Basel)) - "12 phenolic compounds were identified in the samples of T. montanum from six microlocations in Croatia, including nine phenylethanoid glycosides (PGs) with total yields of 30.36-68.06 mg g dw and 25.88-58.88 mg g dw in HAE and MAE extracts, respectively. Echinacoside, teupolioside, stachysoside A, and poliumoside were the most abundant compounds HAE and MAE extracts, making T. montanum an emerging source of PGs."

Journal

A Multi-center, Open-labelled, Randomized, Controlled, Extended Phase Ⅲ Clinical Trial of sIPV Vaccine (clinicaltrials.gov) - P3 | N=1440 | Recruiting | Sponsor: Sinovac Biotech Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease

Immunogenicity of After Primary Immunization and Booster Immunization of sIPV (clinicaltrials.gov) - P=N/A | N=233 | Active, not recruiting | Sponsor: Sinovac Biotech Co., Ltd

New trial • CA6

Safety of Sabin Inactivated Poliovirus Vaccine in Adults, Children and Infants and Lot Consistency Immunogenicity, and Safety of the msIPV in 2 Months Old Infants (clinicaltrials.gov) - P3 | N=1572 | Completed | Sponsor: Sinovac Biotech Co., Ltd | Active, not recruiting ➔ Completed | Trial completion date: Dec 2022 ➔ Jul 2023

Trial completion • Trial completion date • Infectious Disease

A Multi-center, Open-labelled, Randomized, Controlled, Extended Phase Ⅲ Clinical Trial of sIPV Vaccine (clinicaltrials.gov) - P3 | N=1440 | Not yet recruiting | Sponsor: Sinovac Biotech Co., Ltd

New P3 trial • Infectious Disease

Immunogenicity and immune persistence in 4-year-old children completing four doses of Sabin strain or wild strain inactivated poliovirus vaccine: A phase IV, open-labeled, parallel-controlled observational study. (PubMed, Vaccine) - P=N/A | "The neutralizing antibody level is much higher than the seroprotection cutoff (≥1:8) among children of 4 years old who completed the four-dose vaccination of either sIPV or wIPV. Therefore, another booster vaccination is not recommended at 4 years old. Longer immune persistence observation is still ongoing."

Journal • Observational data • P4 data